<DOC>
	<DOCNO>NCT02685462</DOCNO>
	<brief_summary>This Phase 1 , Open-Label , 3-Period , Single-sequence , Drug-drug Interaction Study Healthy Subjects Assess Effect Cenicriviroc Pharmacokinetics ( PK ) HMG-CoA Reductase Inhibitors [ Rosuvastatin ( ROS ) , Atorvastatin ( ATO ) Simvastatin ( SIM ) ] , Caffeine Digoxin</brief_summary>
	<brief_title>Pharmacokinetic Safety Study Cenicriviroc HMG-CoA Reductase Inhibitors , Caffeine Digoxin</brief_title>
	<detailed_description />
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>Be inform nature study provide write informed voluntary consent . Have BMI ≥ 18.0 ≤ 35.0 kg/m2 . Be good general health clinically relevant abnormality base medical history , physical examination , clinical laboratory evaluation ( clinical chemistry , hematology , urinalysis ) , 12lead ECG , opinion Investigator , would affect subject safety . Be able communicate effectively Investigator study center personnel agree comply study procedure restriction . Any disease condition might affect drug absorption , metabolism , excretion , clinically significant cardiovascular , hematological , renal , hepatic , pulmonary , endocrine , gastrointestinal , immunological , dermatological , neurological , psychiatric disease , determine Investigator , necessary , Sponsor 's Medical Monitor . History stomach intestinal surgery , except fully heal appendectomy and/or cholecystectomy allow . Clinically significant illness clinically significant surgery within 4 week administration study medication . History GERD , heartburn , nausea month , similar symptom require regular use antacid , use H2 histamine blocker protonpump inhibitor past 3 month . History achlorhydria , pernicious anemia , peptic ulcer past 6 month . Known suspect hypersensitivity allergic reaction component CVC , ROS , ATO , SIM , Digoxin Caffeine tablet . History malignancy , exception cure basal cell squamous cell carcinoma skin . If female , pregnant breast feeding , positive pregnancy test result prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>